New research from the CPHI Annual Report 2022 predicts that huge volumes of Venture Capital (VC) and Private Equity (PE) cash reserves will drive significant expansion in demand for CRO and CDMO services in the next two years. Writing in the CPHI Annual Report, Brian Scanlan of Edgewater Capital says that, “Despite the economic and inflationary uncertainty, CRO and CDMOs are likely to be the chief beneficiaries of the investment capital that has poured into biotech during the last two years—w...